The bottleneck in modern drug discovery is often not the idea, but the raw material. When researchers are working with precious, hard-to-source primary cells from patients, every microliter wasted is a potential therapeutic insight lost. DropGenie, a Montreal-based biotech startup, is engineering a way around that scarcity by shrinking entire gene-editing workflows down to nanoliter droplets.
Its core technology is a digital microfluidics platform that automates the transfection of compounds into cells at volumes 100 times smaller than conventional methods [Perplexity Sonar Pro Brief]. The promise is straightforward: run more parallel experiments, with higher fidelity, using far fewer cells. For a field increasingly reliant on functional genomics to understand disease, that is a direct path to faster, cheaper discovery.
From Academic Project to Commercial Wedge
The company's origins are a classic deep-tech story, beginning as a research project at McGill University in 2018 that combined digital microfluidics with synthetic-biology techniques [BetaKit, October 2026]. The founding team, led by CEO Alison Hirukawa, a former postdoctoral fellow at McGill's Goodman Cancer Research Centre, saw an opportunity to turn a laboratory tool into a standardized product [BetaKit, October 2026].
Their first commercial offering is the DropGenie Transfection Platform, a device described as a "low volume, high throughput transfection device" for delivering gene-editing payloads like CRISPR-Cas9 ribonucleoproteins (RNPs) into cells [News-Medical, September 2026]. The technical wedge is its ability to handle nonviral delivery into delicate primary cells, which are often more relevant to human biology than immortalized cell lines but are notoriously difficult to work with at scale.
The Three-Pronged Go-to-Market
DropGenie is not just selling a box. The company has articulated a flexible, three-part commercial strategy designed to meet potential customers where they are, which is critical for adoption in conservative, protocol-driven research environments.
- On-premise hardware. Customers can license the DropGenie Transfection Platform to run automated protocols in their own laboratories.
- Study-as-a-service. For organizations that prefer to outsource, DropGenie will conduct the studies and deliver the resulting datasets.
- Strategic data partnerships. The most ambitious model involves forming partnerships to generate standardized, high-dimensional functional datasets from primary patient cells, potentially creating a new asset class [Perplexity Sonar Pro Brief].
This multi-route approach mitigates the classic hardware-sales friction in life sciences, allowing the company to capture value through services and data even if capital equipment sales are slow.
Funding and Strategic Backing
DropGenie has secured a total of $5 million in seed financing across two closes in 2026, attracting investors with both capital and strategic heft. The round was led by BDC Capital's Thrive Fund and Skeleton Key, with participation from the Merck Global Health Innovation Fund, CQDM, Real Ventures, and Anges Québec [BetaKit, October 2026][PR Newswire, June 2026].
The presence of Merck's corporate venture arm is a significant signal, indicating interest from a major pharmaceutical player in the platform's potential to streamline early-stage research. The company has also reported partnerships with pharma giants AbbVie and UCB Pharma, as well as relationships with life-science instrument companies Danaher and Sartorius [BetaKit, October 2026].
| Co-Founder | Role | Key Background |
|---|---|---|
| Alison Hirukawa | CEO | Ph.D., Postdoctoral fellow at McGill University's Goodman Cancer Research Centre [BetaKit, October 2026] |
| Hugo Sinha | COO | Co-founder, based in Cambridge, Massachusetts [BetaKit, October 2026][Success.ai] |
| Philippe Vo | Head of Software / Engineering Lead | Co-founder, based in Brossard, Quebec [SOSV][LinkedIn] |
The Technical Breakdown
At its core, the platform's advantage is a matter of physics and software. By conducting each gene edit within an isolated droplet, the system prevents cross-contamination and enables the layering of multiomic data sets on a per-cell basis [Drug Discovery News]. The company claims the technology achieves high-efficiency knockout in RNP-based editing while dramatically reducing required cell input [DropGenie].
The architecture suggests a focus on integration rather than displacement. The platform is designed to be automation-compatible, slotting into existing laboratory workflows that might use liquid handlers from companies like Danaher, instead of requiring a full rip-and-replace [Perplexity Sonar Pro Brief]. This lowers the adoption barrier for large, established research organizations.
Scaling a Deep-Tech Bet
The risks for DropGenie are those of any company building at the intersection of specialized hardware, complex biology, and enterprise sales. The platform must prove its reliability and reproducibility across different cell types and research groups, a bar that is high in regulated discovery environments. While the partnerships with AbbVie and UCB are promising, they do not yet constitute published, peer-reviewed validation of the platform's impact on drug development timelines.
Furthermore, the commercial model, while clever, adds operational complexity. Managing a mix of hardware deployments, service work, and long-term data partnerships requires distinct sales, support, and scientific teams. The company's ability to execute on all three fronts simultaneously, with a seed-stage budget and team, will be tested as it moves from early access to broader commercialization.
The next twelve months will likely focus on converting pilot integrations into recurring revenue streams and expanding the library of validated protocols. The backing from Merck and BDC provides not just capital, but a runway to prove that miniaturization can indeed translate into accelerated biological discovery. For drug hunters working with the rarest of patient cells, that proof can't come soon enough.
Sources
- [BetaKit, October 2026] DropGenie raises $5 million USD backed by BDC to speed up biological discovery | https://betakit.com/dropgenie-raises-5-million-usd-backed-by-bdc-to-speed-up-biological-discovery/
- [PR Newswire, June 2026] DropGenie Raises Seed+ Financing to Accelerate Commercialization of Its First Product | https://www.prnewswire.com/news-releases/dropgenie-raises-seed-financing-to-accelerate-commercialization-of-its-first-product-302804959.html
- [News-Medical, September 2026] Streamlining CRISPR workflows, from editing to analysis | https://www.news-medical.net/news/20260930/Streamlining-CRISPR-workflows-from-editing-to-analysis.aspx
- [Drug Discovery News] Editing precious patient cells in a single drop | https://www.drugdiscoverynews.com/editing-precious-patient-cells-in-a-single-drop-16331
- [DropGenie] Company website | https://dropgenie.com/
- [SOSV] Company profile | https://engine.xyz/resident-companies/dropgenie
- [LinkedIn] Philippe Vo profile | https://ca.linkedin.com/in/philippe-vo-155962124